Key Insights

Highlights

Success Rate

67% trial completion

Treatment Research

9 treatments under study, led by Bevacizumab

Research Leaders

5 sponsors active, led by National Cancer Institute (NCI)

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

66.7%

-19.9% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed with results

Key Signals

2 with results67% success

Data Visualizations

Phase Distribution

4Total
Not Applicable (2)
Phase 2 (2)

Trial Status

Completed2
Terminated1
Withdrawn1

Trial Success Rate

66.7%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT01125046Phase 2Completed

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

NCT01234805Not ApplicableTerminated

Yoga Therapy in Treating Patients With Malignant Brain Tumors

NCT02194452Not ApplicableWithdrawn

Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors

NCT00492089Phase 2Completed

Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer

Showing all 4 trials

Research Network

Common Treatments

  • Bevacizumab2
  • Qualityoflife Assessment2
  • Laboratory Biomarker Analysis1
  • Positron Emission Tomography1
  • Questionnaire Administration1

Active Sponsors

  • National Cancer Institute (NCI)3
  • Northwestern University1
  • Sue O'Dorisio1
  • Wake Forest University Health Sciences1
  • Ride for Kids1

Top Investigators

Related Conditions

  • Adult Papillary Meningioma4
  • Recurrent Adult Brain Tumor4
  • Adult Grade Ii Meningioma4
  • Adult Ependymoma4
  • Adult Choroid Plexus Tumor3

Activity Timeline